LB Pharmaceuticals Inc Common Stock
LBRXStock
$30.59
Market Cap$922.24M
P/E—
Div yield—
Beta1.24
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)43.76%
Price vs S&P 500 (4W)15.67%
VGM Score70.04
Market Capitalization$922.24M
Earnings Surprise History
Q1 26-0.67est. -0.76
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.30
4.30
4.25
4.25
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LBRXLB Pharmaceuticals Inc Common Stock | — | — | B | $30.59 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing therapies for neuropsychiatric disorders including schizophrenia and bipolar depression. Its lead candidate, LB-102, is a novel benzamide antipsychotic with the potential to be the first of its kind approved in the United States, based on amisulpride, an antipsychotic already approved in over 50 countries.